Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Martin, Petra ^a   Noonan, Sinead ^a   Mullen, Michael P ^b   Scaife, Caitriona ^b   Tosetto, Miriam ^a   Nolan, Blathnaid ^a   Wynne, Kieran ^b   Hyland, John ^a   Sheahan, Kieran ^a   Elia, Giuliano ^b   O'Donoghue, Diarmuid ^a   Fennelly, David ^a   O'Sullivan, Jacintha ^c  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

2D DIGE; Bevacizumab; Biomarker; Colorectal cancer; Proteomics

Indexed keywords

ANGIOTENSINOGEN; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN E; BEVACIZUMAB; CAPECITABINE PLUS OXALIPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN INHIBITOR; VITAMIN D BINDING PROTEIN; AGT PROTEIN, HUMAN; DBP PROTEIN, HUMAN; DNA BINDING PROTEIN; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; ANTIBODY AFFINITY; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MALE; METASTATIC COLORECTAL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SURVIVAL TIME; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; UPREGULATION; VALIDATION PROCESS; AGED; BLOOD; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION REGULATION; METASTASIS; MIDDLE AGED; PROTEOMICS; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSINOGEN; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOLIPOPROTEINS E; BEVACIZUMAB; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEOMICS; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 84924361682     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-887     Document Type: Article

References (45)

1. Ponz-Sarvisé M, Rodríguez J, Viudez A, Chopitea A, Calvo A, García-Foncillas J, Gil-Bazo I: Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new? World J Gastroenterol 2007, 13:5877-5887. 10.3748/wjg.v13.i44.5877
2. Bardelli A, Siena S: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010, 28:1254-61. 10.1200/JCO.2009.24.6116
3. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N: Colorectal cancer. Lancet 2010, 375:1030-47. 10.1016/S0140-6736(10)60353-4
4. Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, Pessi MA, Prochilo T, Quadri A, Gatta G, de Braud F, Wils J: Colon cancer. Crit Rev Oncol Hematol 2010, 74:106-33. 10.1016/j.critrevonc.2010.01.010
5. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-17. 10.1056/NEJMoa0805019
6. Luo HY, Xu RH: Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World J Gastroenterol 2014, 20:3858-74. 10.3748/wjg.v20.i14.3858
7. Custodio A, Barriuso J, de Castro J, Martinez-Marin V, Moreno V, Rodriguez-Salas N, Feliu J: Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives. Cancer Treat Rev 2013, 39:908-24. 10.1016/j.ctrv.2013.02.004
8. Hegde PS, Jubb AM, Chen D, Li NF, Meng YG, Bernaards C, Elliott R, Scherer SJ, Chen DS: Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res 2013, 19:929-37. 10.1158/1078-0432.CCR-12-2535
9. Keskin M, Ustuner Z, Dincer M, Etiz D, Celik HE, Gulbas Z: Importance of serum VEGF and basic FGF levels in determining response to treatment and survival in patients with metastatic colorectal cancer. J Clin Oncol 2012, 30:(suppl; abstr e21050).
10. Jubb AM, Harris AL: Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010, 11:1172-83. 10.1016/S1470-2045(10)70232-1
11. Collinson F, Hutchinson M, Craven RA, Cairns DA, Zougman A, Wind TC, Gahir N, Messenger MP, Jackson S, Thompson D, Adusei C, Ledermann JA, Hall G, Jayson GC, Selby PJ, Banks RE: Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res 2013, 19:5227-39. 10.1158/1078-0432.CCR-13-0489
12. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-9. 10.1200/JCO.2007.14.9930
13. Byrne JC, Downes MR, O'Donoghue N, O'Keane C, O'Neill A, Fan Y, Fitzpatrick JM, Dunn M, Watson RW: 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res 2009, 8:942-57. 10.1021/pr800570s
14. Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S: AmiGO: online access to ontology and annotation data. Bioinformatics 2009, 25:288-289. 10.1093/bioinformatics/btn615
15. Mullen MP, Elia G, Hilliard M, Parr MH, Diskin MG, Evans AC, Crowe MA: Proteomic characterization of histotroph during the preimplantation phase of the estrous cycle in cattle. J Proteome Res 2012, 11:3004-18. 10.1021/pr300144q
16. Mahley RW, Rall SC: Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000, 1:507-537. 10.1146/annurev.genom.1.1.507
17. Vogel T, Guo NH, Guy R, Drezlich N, Krutzsch HC, Blake DA, Panet A, Roberts DD: Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J Cell Biochem 1994, 54:299-308. 10.1002/jcb.240540306
18. Tarnus E, Wassef H, Carmel JF, Rondeau P, Roche M, Davignon J, Bernier L, Bourdon E: Apolipoprotein E limits oxidative stress-induced cell dysfunctions in human adipocytes. FEBS Lett 2009, 58:2042-8.
19. Venanzoni MC, Giunta S, Muraro GB, Storari L, Crescini C, Mazzucchelli R, Montironi R, Seth A: Apolipoprotein E expression in localized prostate cancers. Int J Oncol 2003, 22:779-86.
20. Chen YC, Pohl G, Wang TL, Morin PJ, Risberg B, Kristensen GB, Yu A, Davidson B, Shih IM: Apolipoprotein E Is required for cell proliferation and survival in ovarian cancer. Cancer Res 2005, 65:331-337.
21. Sakashita K, Tanaka F, Zhang X, Mimori K, Kamohara Y, Inoue H, Sawada T, Hirakawa K, Mori M: Clinical significance of ApoE expression in human gastric cancer. Onc Rep 2008, 20:1313-1319.
22. Slattery ML, Sweeney C, Murtaugh M, Ma KN, Potter JD, Levin TR, Samowitz W, Wolff R: Associations between apoE genotype and colon and rectal cancer. Carcinogenesis 2005, 26:1422-1429. 10.1093/carcin/bgi088
23. Ramos JG, Varayoud J, Bosquiazzo VL, Luque EH, Munoz-de-Toro M: Cellular turnover in the rat uterine cervix and its relationship to estrogen and progesterone receptor dynamics. Biol Reprod 2002, 67:735-742. 10.1095/biolreprod.101.002402
24. Bhattacharjee PS, Huq TS, Mandal TK, Graves RA, Muniruzzaman S, Clement C, McFerrin HE, Hill JM: A novel peptide derived from human apolipoprotein E is an inhibitor of tumor growth and ocular angiogenesis. PLoS One 2011, 6:e15905. 10.1371/journal.pone.0015905
25. Speeckaert M, Huang G, Delanghe JR, Taes YE: Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006, 372:33-42. 10.1016/j.cca.2006.03.011
26. Kim BK, Lee JW, Park PJ, Shin YS, Lee WY, Lee KA, Ye S, Hyun H, Kang KN, Yeo D, Kim Y, Ohn SY, Noh DY, Kim CW: The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res 2009, 11:R22. 10.1186/bcr2247
27. Bijian K, Mlynarek AM, Balys RL, Jie S, Xu Y, Hier MP, Black MJ, Di Falco MR, LaBoissiere S, Alaoui-Jamali MA: Serum proteomic approach for the identification of serum biomarkers contributed by oral squamous cell carcinoma and host tissue microenvironment. J Proteome Res 2009, 8:2173-2185. 10.1021/pr800979e
28. Turner AM, McGowan L, Millen A, Rajesh P, Webster C, Langman G, Rock G, Tachibana I, Tomlinson MG, Berditchevski F, Naidu B: Circulating DBP level and prognosis in operated lung cancer: an exploration of pathophysiology. Eur Respir J 2013, 41:410-416. 10.1183/09031936.00002912
29. Weinstein SJ, Stolzenberg-Solomon RZ, Kopp W, Rager H, Virtamo J, Albanes D: Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study. Cancer Res 2012, 72:1190-8. 10.1158/0008-5472.CAN-11-2950
30. Powe CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankers E, Wenger J, Karumanchi SA, Thadhani R, Bhan I: Vitamin D-bi Bouquet C, Lamandé N, Brand M, Gasc JM, Jullienne B, Faure Gnding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res 2011, 26:1609-16. 10.1002/jbmr.387
31. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, Willett WC: Prospective study of predictors of vitamin d status and cancer incidence and mortality in men. J Natl Cancer Inst 2006, 98:451-459. 10.1093/jnci/djj101
32. Bai YH, Lu H, Hong D, Lin CC, Yu Z, Chen BC: Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic meta-analysis. World J Gastroenterol 2012, 18:1672-9. 10.3748/wjg.v18.i14.1672
33. Woolcott CG, Wilkens LR, Nomura AM, Horst RL, Goodman MT, Murphy SP, Henderson BE, Kolonel LN, Le Marchand L: Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2010, 19:130-134. 10.1158/1055-9965.EPI-09-0475
34. Wu K, Feskanich D, Fuchs CS, Chan AT, Willett WC, Hollis BW, Pollak MN, Giovannucci E: Interactions between plasma levels of 25-Hydroxyvitamin D, insulin-like growth factor (IGF)-1 and C-peptide with risk of colorectal cancer. PLoS One 2011, 6:e28520. 10.1371/journal.pone.0028520
35. Yamamoto N, Suyama H, Nakazato H, Yamamoto N, Koga Y: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. Cancer Immunol Immunother 2008, 57:1007-1016. 10.1007/s00262-007-0431-z
36. Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D'Amato R, Zetter B, Folkman J, Ray R, Swamy N, Pirie-Shepherd S: Vitamin D binding protein-macrophage activating factor (DBP- maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003, 5:32-40. 10.1016/S1476-5586(03)80015-5
37. Chakraborti CK: Vitamin D as a promising anticancer agent. Indian J Pharmacol 2011, 43:113-120. 10.4103/0253-7613.77335
38. Kanda S, Mochizuki Y, Miyata Y, Kanetake H, Yamamoto N: Effects of vitamin -D3-binding protein - derived macrophage activating factor (GcMAF) on angiogenesis. J Natl Cancer Inst 2002, 94:1311-1319. 10.1093/jnci/94.17.1311
39. Gregory KJ, Zhao B, Bielenberg DR, Dridi S, Wu J, Jiang W, Huang B, Pirie-Shepherd S, Fannon M: Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One 2010, 5:e13428. 10.1371/journal.pone.0013428
40. Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ: 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther 2007, 6:1433-9.
41. Iseki K, Tatsuta M, Uehara H, Iishi H, Yano H, Sakai N, Ishiguro S: Inhibition of angiogenesis as a mechanism for inhibition by 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 1999, 81:730-3. 10.1002/(SICI)1097-0215(19990531)81:5<730::AID-IJC11>3.0.CO;2-Q
42. Vincent F, Bonnin P, Clemessy M, Contrerès JO, Lamandé N, Gasc JM, Vilar J, Hainaud P, Tobelem G, Corvol P, Dupuy E: Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. Cancer Res 2009, 69:2853-2860. 10.1158/0008-5472.CAN-08-2484
43. Tewksbury DA, Frome WL, Dumas ML: Characterization of human angiotensinogen. J Biol Chem 1978, 253:3817-3820.
44. Bouquet C, Lamandé N, Brand M, Gasc JM, Jullienne B, Faure G, Griscelli F, Opolon P, Connault E, Perricaudet M, Corvol P: Suppression of angiogenesis, tumor growth, and metastasis by adenovirus-mdiated gene transfer of human angiotensinogen. Mol Therapy 2006, 14:175-182. 10.1016/j.ymthe.2006.01.017
45. Brand M, Lamandé N, Larger E, Corvol P, Gasc JM: Angiotensinogen impairs angiogenesis in the chick chorioallantoic membrane. J Mol Med 2007, 85:451-60. 10.1007/s00109-006-0141-6